Merck has opened a secondary packaging facility to churn out vaccines and biologics. It also announced another plant that will produce inhalers and is set for completion in 2026.

Merck's fill-finish facility in Singapore now includes a vial-packaging line to produce cancer treatment Keytruda and three syringe-packaging lines to manufacture another Merck mega-blockbuster, HPV vaccine Gardasil.

The site began the sterile fill of Keytruda into vials last year. Its expansion includes cold storage and a new quality control laboratory.

Both factories are located within Merck’s 72-acre manufacturing campus in Tuas, Singapore. Merck opened its first plant in Singapore in 1997. The new facilities are part of an outlay of up to $500 million, which brings Merck’s total investment over nearly three decades in Singapore to $2 billion.